Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy

Advances in molecular biology and genetics have contributed to breakthrough treatments directed at specific pathways associated with the development of cancer. Small‐molecule inhibitors (Nibs) aimed at a variety of cellular pathways have been efficacious; however, they are associated with significant dermatologic toxicities.

[1]  S. Nisticò,et al.  Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review , 2021, Drug Safety.

[2]  V. Torri,et al.  Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. , 2021, European journal of cancer.

[3]  M. Fassan,et al.  PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer , 2021, Frontiers in Oncology.

[4]  W. Liang,et al.  Toxicity Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Patients with Lung Cancer: A Systematic Review and Network Meta-Analysis. , 2021, Critical reviews in oncology/hematology.

[5]  Yan Niu,et al.  Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer. , 2021, European journal of medicinal chemistry.

[6]  A. Oza,et al.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. , 2021, The Lancet. Oncology.

[7]  R. Hakem,et al.  Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand , 2021, Oncogene.

[8]  S. Johnston,et al.  Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience , 2021, Breast Cancer Research and Treatment.

[9]  Michael L. Wang,et al.  Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study , 2021, The Lancet.

[10]  Douglas B. Johnson,et al.  Defining and Targeting BRAF Mutations in Solid Tumors , 2021, Current Treatment Options in Oncology.

[11]  J. Bridgewater,et al.  Targeting FGFR inhibition in cholangiocarcinoma. , 2021, Cancer treatment reviews.

[12]  J. Vizmanos,et al.  A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative Neoplasms , 2021, Cancers.

[13]  J. Neal,et al.  Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial. , 2021, Cancer discovery.

[14]  W. Jacot,et al.  Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer , 2021, Expert opinion on pharmacotherapy.

[15]  L. Requena,et al.  Cutaneous eruption with reactive endothelial atypia due to emerging targeted cancer therapies: Report of two cases with clinico‐pathologic correlation , 2021, Journal of cutaneous pathology.

[16]  B. Melichar,et al.  Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial. , 2021, Oral oncology.

[17]  F. Worden,et al.  Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial. , 2021, Oral oncology.

[18]  Adedeji K. Adebayo,et al.  Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer , 2020, Cancers.

[19]  A. Morrone,et al.  Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)–Like Pigmentation in a Metastatic Breast Cancer Patient , 2020, Journal of breast cancer.

[20]  D. Nation,et al.  Role of Notch signaling in neurovascular aging and Alzheimer's disease. , 2020, Seminars in cell & developmental biology.

[21]  Hui-Zi Chen,et al.  Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance , 2020, British Journal of Cancer.

[22]  R. Latagliata,et al.  Second primary malignancy in myelofibrosis patients treated with ruxolitinib , 2020, British journal of haematology.

[23]  M. Lacouture,et al.  Prevention and Management of Dermatological Toxicities Related to Anticancer Agents: ESMO Clinical Practice Guidelines†. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  K. Glazebrook,et al.  BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series , 2020, Skeletal Radiology.

[25]  Yuankai Shi,et al.  Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances , 2020, Leukemia.

[26]  D. Mahadevan,et al.  Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics , 2020, Expert opinion on investigational drugs.

[27]  A. Lallas,et al.  Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits , 2020, Expert opinion on drug safety.

[28]  N. LeBoeuf,et al.  Fibroblast Growth Factor Receptor Inhibitors and Nonuremic Calciphylaxis. , 2020, JAMA dermatology.

[29]  M. Lacouture,et al.  Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines , 2020, The oncologist.

[30]  G. Roti,et al.  Targeting Notch Trafficking and Processing in Cancers , 2020, Cells.

[31]  J. Lapins,et al.  Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma , 2020, Acta dermato-venereologica.

[32]  M. Sachdeva,et al.  Stevens Johnson Syndrome and Toxic Epidermal Necrolysis Reactions to BRAF and MEK Inhibitors in Patients with Melanoma: A Systematic Review. , 2020, Journal of the American Academy of Dermatology.

[33]  J. Soria,et al.  Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer , 2020, Investigational New Drugs.

[34]  N. Khan,et al.  Bullous Skin Rash: A Rare Case of Palbociclib-Induced Dermatological Toxicity , 2020, Cureus.

[35]  R. Kim,et al.  Dabrafenib‐induced neutrophilic panniculitis in a child undergoing dual BRAF‐MEK inhibitor therapy for glioblastoma multiforme , 2020, Pediatric dermatology.

[36]  R. Botella-Estrada,et al.  Systematic review of BRAF/MEK inhibitors‐induced Severe Cutaneous Adverse Reactions (SCARs) , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[37]  W. Eiermann,et al.  Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  A. Pileri,et al.  Cutaneous adverse‐events in patients treated with Ibrutinib , 2020, Dermatologic therapy.

[39]  Nozomi Tani,et al.  Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation—A Case Report and a Review of the Literature , 2020, Medicina.

[40]  E. Baudin,et al.  Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer , 2020, Endocrine.

[41]  K. Wilner,et al.  Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) , 2020, Breast Cancer Research and Treatment.

[42]  S. Chon,et al.  Cutaneous Effects of Notch Inhibitor Therapy: A Report of Two Cases , 2020, Case reports in dermatological medicine.

[43]  C. Récher,et al.  Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors , 2020, American Journal of Clinical Dermatology.

[44]  D. Lake,et al.  Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer , 2020, Breast Cancer Research and Treatment.

[45]  T. Biedermann,et al.  Vemurafenib‐related photosensitivity , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[46]  J. Kirkwood,et al.  Clinical Development of BRAF plus MEK Inhibitor Combinations. , 2020, Trends in cancer.

[47]  P. Guglielmelli,et al.  Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review , 2020, International journal of molecular sciences.

[48]  R. Elstrom,et al.  Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase , 2020, Clinical Cancer Research.

[49]  S. Heo,et al.  Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. , 2020, Cancer discovery.

[50]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[51]  B. McLellan,et al.  Anticancer therapies associated with secondary cutaneous malignancies: a review of the literature. , 2020, Journal of the American Academy of Dermatology.

[52]  Yi-long Wu,et al.  Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer , 2020, Expert opinion on drug safety.

[53]  J. Byrd,et al.  Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial , 2020, The Lancet.

[54]  G. Argenziano,et al.  A case of discoid lupus erythematosus because of palbociclib , 2020, Journal of cutaneous pathology.

[55]  D. Hyman,et al.  Small molecules, big impact: 20 years of targeted therapy in oncology , 2020, The Lancet.

[56]  R. Nazarian,et al.  Subacute cutaneous lupus erythematosus with positive anti‐Ro antibodies following palbociclib and letrozole treatment: A case report and literature review , 2020, Journal of cutaneous pathology.

[57]  Jean-Yves Blay,et al.  Evolving role of regorafenib for the treatment of advanced cancers. , 2020, Cancer treatment reviews.

[58]  J. Sanches,et al.  Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel☆☆☆ , 2020, Anais brasileiros de dermatologia.

[59]  Shanker Kalyana-Sundaram,et al.  Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors , 2020, Cancer Chemotherapy and Pharmacology.

[60]  P. Rerknimitr,et al.  Osimertinib-associated ashy dermatosis–like hyperpigmentation , 2020, JAAD case reports.

[61]  Thomas McFarlane,et al.  Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. , 2020, Annals of palliative medicine.

[62]  A. LaCasce,et al.  Cutaneous Eruptions from Ibrutinib Resembling EGFR Inhibitor-Induced Dermatologic Adverse Events. , 2019, Journal of the American Academy of Dermatology.

[63]  F. Marmé,et al.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.

[64]  A. Lyon,et al.  Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer. , 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

[65]  A. Maderal,et al.  Chronic cutaneous lupus erythematosus (discoid lupus) induced by palbociclib , 2019, International journal of dermatology.

[66]  G. Mills,et al.  Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer , 2019, International journal of cancer.

[67]  G. Lask,et al.  Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma , 2019, Current Treatment Options in Oncology.

[68]  A. Yorulmaz,et al.  Paronychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report , 2019, Skin Appendage Disorders.

[69]  I. Berindan‐Neagoe,et al.  A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer , 2019, Cancers.

[70]  B. Kaffenberger,et al.  Cutaneous Adverse Reactions of Anticancer Agents. , 2019, Dermatologic clinics.

[71]  X. Q. Koh,et al.  Ibrutinib‐associated T‐cell pseudolymphoma , 2019, Clinical and experimental dermatology.

[72]  E. Ciruelos,et al.  Ribociclib-Related Stevens–Johnson Syndrome: Oncologic Awareness, Case Report, and Literature Review , 2019, Journal of breast cancer.

[73]  R. Elstrom,et al.  Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. , 2019, Blood.

[74]  C. Rossi,et al.  Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera , 2019, In Vivo.

[75]  G. Fabbrocini,et al.  Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer , 2019, Clinical Drug Investigation.

[76]  V. Soriano,et al.  Dusky erythema secondary to anti-MEK therapy. , 2019, Melanoma research.

[77]  P. Nuciforo,et al.  FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  Ankur Jain.  Imatinib Induced Complete Remission of Psoriasis in a Patient with Chronic Myeloid Leukemia , 2019, Indian Journal of Hematology and Blood Transfusion.

[79]  G. Mills,et al.  Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation , 2019, Breast Cancer Research.

[80]  J. Byrd,et al.  Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. , 2019, Blood advances.

[81]  M. Jefford,et al.  The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors , 2019, Journal of Cancer Survivorship.

[82]  C. Dasanu.  Erythematous skin lesions with necrotic centers on lower extremities due to the use of ruxolitinib for primary myelofibrosis , 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[83]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[84]  J. Byrd,et al.  Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. , 2019, Blood advances.

[85]  Y. Sugimoto,et al.  Regorafenib-Induced Hand–Foot Skin Reaction Is More Severe on the Feet Than on the Hands , 2019, Oncology research.

[86]  L. Heinzerling,et al.  Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management , 2019, ESMO Open.

[87]  K. Peris,et al.  Ibrutinib‐associated palmo‐plantar fissures in a patient with Chronic Lymphocytic Leukaemia: a novel cutaneous adverse event , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[88]  J. Arrese,et al.  Granulomatous Reactions from Tattoos Following BRAF Inhibitor Therapy , 2019, Case Reports in Dermatology.

[89]  S. Paydaş.  Management of adverse effects/toxicity of ibrutinib. , 2019, Critical reviews in oncology/hematology.

[90]  K. Tamura,et al.  BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[91]  L. Fearfield,et al.  BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases. , 2019, The American Journal of dermatopathology.

[92]  A. Iafrate,et al.  A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations , 2019, Clinical Cancer Research.

[93]  C. Massone,et al.  Ibrutinib and Pyoderma Gangrenosum in a Patient With B-Cell Chronic Lymphocytic Leukemia. , 2019, The American Journal of dermatopathology.

[94]  J. Ajani,et al.  A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. , 2019, European journal of cancer.

[95]  H. Iwata,et al.  MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer , 2019, npj Breast Cancer.

[96]  A. Sood,et al.  Exploring and comparing adverse events between PARP inhibitors. , 2019, The Lancet. Oncology.

[97]  Hui-Zi Chen,et al.  Metastatic Calcinosis Cutis Associated With a Selective FGFR Inhibitor. , 2019, JAMA dermatology.

[98]  M. Ychou,et al.  Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. , 2018, The oncologist.

[99]  Yang Yu,et al.  Development of Aggressive Squamous Cell Carcinoma With Perineural Invasion During Ruxolitinib Treatment. , 2018, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[100]  Mary Albrethsen,et al.  Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies—A single institution experience and a review of literature , 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[101]  D. Saceda‐Corralo,et al.  Adverse Hair Reactions to New Targeted Therapies for Cancer. , 2019, Actas dermo-sifiliograficas.

[102]  W. Akerley,et al.  Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. , 2019, The oncologist.

[103]  T. Zuberbier,et al.  Olaparib Desensitization in a Patient with Recurrent Peritoneal Cancer. , 2018, The New England journal of medicine.

[104]  O. Mir,et al.  Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours. , 2018, European journal of cancer.

[105]  C. Grávalos,et al.  Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology , 2018, Clinical and Translational Oncology.

[106]  B. Zhang,et al.  Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials , 2018, OncoTargets and therapy.

[107]  M. Campone,et al.  Cutaneous and Gastrointestinal Leukocytoclastic Vasculitis Induced by Palbociclib in a Metastatic Breast Cancer Patient: A Case Report , 2018, Clinical breast cancer.

[108]  E. Muñoz-Couselo,et al.  DRESS syndrome due to vemurafenib treatment: switching BRAF inhibitor to solve a big problem , 2018, BMJ Case Reports.

[109]  J. Soria,et al.  First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[110]  W. Eiermann,et al.  Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.

[111]  Ravi C. Patel,et al.  Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor , 2018, Journal of cutaneous pathology.

[112]  A. Korman,et al.  Subclinical granulomas in benign skin lesions heralding the onset of BRAF and MEK inhibitor–associated granulomatous dermatitis in a patient with metastatic melanoma , 2018, JAAD case reports.

[113]  M. Grossman,et al.  Chemotherapy patient with Stevens‐Johnson Syndrome presents to the Emergency Department: A case report , 2018, The American journal of emergency medicine.

[114]  J. Lear,et al.  Hedgehog pathway inhibition by topical patidegib to reduce BCC burden in patients with basal cell nevus (Gorlin) syndrome. , 2018 .

[115]  J. Brown,et al.  Pityriasis rubra pilaris‐like erythroderma secondary to phosphoinositide 3‐kinase inhibition , 2018, Clinical and experimental dermatology.

[116]  L. Spring,et al.  Stevens-Johnson syndrome–like eruption from palbociclib in a patient with metastatic breast cancer , 2018, JAAD case reports.

[117]  J. Reynolds,et al.  Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib , 2018, World journal of oncology.

[118]  Henry Tsai,et al.  Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis , 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[119]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[120]  H. Gray,et al.  Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. , 2018, Gynecologic oncology.

[121]  K. Flaherty,et al.  Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC). , 2018 .

[122]  R. Hui,et al.  Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies , 2018, Journal of immunology research.

[123]  G. Stingl,et al.  Staphylococcal Scalded Skin Syndrome Caused by a Rare Variant of Exfoliative-toxin-A+ S. aureus in an Adult Immunocompromised Woman. , 2018, Acta dermato-venereologica.

[124]  R. Mössner,et al.  Stevens‐Johnson syndrome/toxic epidermal necrolysis overlap in a NSCLC patient treated with afatinib , 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[125]  D. Kontoyiannis,et al.  Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[126]  S. Granter,et al.  Subacute Cutaneous Lupus Erythematosus Induced by Palbociclib , 2018, Journal of cutaneous medicine and surgery.

[127]  R. Advani,et al.  Ibrutinib‐associated rash: a single‐centre experience of clinicopathological features and management , 2018, British journal of haematology.

[128]  R. Dummer,et al.  Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[129]  Stephanie Bayers,et al.  Self-limiting Ibrutinib-Induced Neutrophilic Panniculitis. , 2017, The American Journal of dermatopathology.

[130]  D. Ghez,et al.  Ibrutinib-Induced Neutrophilic Dermatosis , 2017, The American Journal of dermatopathology.

[131]  S. Loi,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. , 2017, The New England journal of medicine.

[132]  A. Hauschild,et al.  Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. , 2017, European journal of cancer.

[133]  M. Lacouture,et al.  Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta‐analysis , 2017, Journal of the American Academy of Dermatology.

[134]  James X. Sun,et al.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[135]  M. Goetz,et al.  MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  V. Talwar,et al.  Unusual Pattern of Whitening of Eyebrows Following Sunitinib Therapy: A Case Report with Brief Review of Literature , 2017, International journal of trichology.

[137]  W. Gradishar,et al.  Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib. , 2017, Breast.

[138]  M. Espié,et al.  Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. , 2017, The Lancet. Oncology.

[139]  B. Han,et al.  First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[140]  Julie H Wu,et al.  BRAF inhibitor‐associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management , 2017, The British journal of dermatology.

[141]  M. Chren,et al.  Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib , 2017, Journal of the American Academy of Dermatology.

[142]  M. Aria,et al.  Drug-induced oral lichenoid reactions: a real clinical entity? A systematic review , 2017, European Journal of Clinical Pharmacology.

[143]  R. Nijhawan,et al.  Development of Basal Cell Carcinoma With Squamous Differentiation During Vismodegib Treatment. , 2017, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[144]  P. Neven,et al.  MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  C. Hudis,et al.  MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer , 2017, Clinical Cancer Research.

[146]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[147]  F. d'Amore,et al.  Ibrutinib-Associated Skin Toxicity: A Case of Maculopapular Rash in a 79-Year Old Caucasian Male Patient with Relapsed Waldenstrom’s Macroglobulinemia and Review of the Literature , 2017, Dermatology reports.

[148]  J. Dipersio,et al.  Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial , 2017, Journal of Hematology & Oncology.

[149]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[150]  M. Schlumberger,et al.  Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes , 2017, Endocrine.

[151]  Suzanne F. Jones,et al.  Circulating copper and zinc levels and risk of hepatobiliary cancers in Europeans , 2017, British Journal of Cancer.

[152]  J. Wargo,et al.  Diverse types of dermatologic toxicities from immune checkpoint blockade therapy , 2017, Journal of cutaneous pathology.

[153]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[154]  S. Zerdoud,et al.  Development of Photoonycholysis with Vandetanib Therapy , 2016, Skin Appendage Disorders.

[155]  A. Kubba,et al.  Imatinib mesylate-induced pseudoporphyria in a patient with chronic myeloid leukemia , 2016, Indian journal of dermatology, venereology and leprology.

[156]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[157]  A. Hauschild,et al.  Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma , 2016, The oncologist.

[158]  T. Manabe,et al.  Stevens-Johnson syndrome-like erosive dermatitis possibly related to afatinib , 2016, European Journal of Dermatology.

[159]  G. Nuovo,et al.  Cutaneous, Purpuric Painful Nodules Upon Addition of Ibrutinib to RCVP Therapy in a CLL Patient: A Distinctive Reaction Pattern Reflecting Iatrogenic Th2 to Th1 Milieu Reversal , 2016, The American Journal of dermatopathology.

[160]  R. Finn,et al.  Treating cancer with selective CDK4/6 inhibitors , 2016, Nature Reviews Clinical Oncology.

[161]  G. Marti,et al.  Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia. , 2016, JAMA dermatology.

[162]  Veronica J Shi,et al.  Cutaneous manifestations of nontargeted and targeted chemotherapies. , 2016, Seminars in oncology.

[163]  Ji-Hye Park,et al.  Exacerbation of Psoriasis after Imatinib Mesylate Treatment , 2016, Annals of dermatology.

[164]  T. Barbui,et al.  Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis , 2016, Leukemia.

[165]  A. Henry,et al.  Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma. , 2016, JAMA dermatology.

[166]  K. Tsai,et al.  BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. , 2016, Human pathology.

[167]  M. Lacouture.  Management of Dermatologic Toxicities Associated With Targeted Therapy , 2016, Journal of the advanced practitioner in oncology.

[168]  M. Gönül,et al.  Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature , 2016, Dermatology research and practice.

[169]  M. Kodaira,et al.  Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors , 2016, Cancer Chemotherapy and Pharmacology.

[170]  Jeffrey A Jones,et al.  Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.

[171]  M. Ellis,et al.  A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer , 2016, Clinical Cancer Research.

[172]  T. Kijima,et al.  Successful treatment with gefitinib after Stevens–Johnson syndrome associated with afatinib therapy in a patient with adenocarcinoma of the lung , 2016, International Cancer Conference Journal.

[173]  F. Kubba,et al.  Acute generalized exanthematous pustulosis (AGEP) secondary to imatinib in a patient with chronic myeloid leukaemia , 2015, Clinical and experimental dermatology.

[174]  M. Staehler,et al.  SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. , 2015, European urology.

[175]  J. Larkin,et al.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. , 2015, The Lancet. Oncology.

[176]  J. Larkin,et al.  Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation‐positive metastatic melanoma, including recognition and management of rare presentations , 2015, The British journal of dermatology.

[177]  A. Menzies,et al.  Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. , 2015, JAMA dermatology.

[178]  Wei Li,et al.  RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors. , 2015, Cancer research.

[179]  Jeffrey A Jones,et al.  Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias. , 2015, JAMA oncology.

[180]  A. Hezel,et al.  Phase 2 study of MK‐2206, an allosteric inhibitor of AKT, as second‐line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005) , 2015, Cancer.

[181]  Ying Cheng,et al.  Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2015, The Lancet. Oncology.

[182]  S. Krishnamoorthy,et al.  Management of regorafenib-related toxicities: a review , 2015, Therapeutic advances in gastroenterology.

[183]  J. Firth,et al.  Sweet syndrome as terminal event in ruxolitinib‐treated myelofibrosis , 2015, British journal of haematology.

[184]  H. Mackay,et al.  A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. , 2015, Gynecologic oncology.

[185]  J. Olson,et al.  Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study , 2015, Child's Nervous System.

[186]  A. Hood,et al.  A rare case of late-onset lichenoid photodermatitis after vandetanib therapy , 2015, JAAD case reports.

[187]  Sung-Bae Kim,et al.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. , 2015, The New England journal of medicine.

[188]  Likun Chen,et al.  Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer , 2015, Chinese journal of cancer.

[189]  Thomas E. Hughes,et al.  Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[190]  M. Griesshammer,et al.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera. , 2015, The New England journal of medicine.

[191]  S. Welsh,et al.  Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma , 2015, Therapeutic advances in medical oncology.

[192]  O. Abdel-Rahman,et al.  Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis , 2015, Expert review of anticancer therapy.

[193]  R. Kefford,et al.  Cutaneous adverse events in patients treated with BRAF inhibitor‐based therapies for metastatic melanoma for longer than 52 weeks , 2015, The British journal of dermatology.

[194]  M. Anadkat,et al.  MEK inhibitor-induced dusky erythema: characteristic drug hypersensitivity manifestation in 3 patients. , 2015, JAMA dermatology.

[195]  A. Daud,et al.  Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. , 2014, Journal of the American Academy of Dermatology.

[196]  R. Kefford,et al.  Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib , 2014, The Australasian journal of dermatology.

[197]  P. Fernández-Peñas,et al.  Dabrafenib‐associated necrobiotic granulomatous reaction , 2014, The Australasian journal of dermatology.

[198]  J. Fournier,et al.  Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib. , 2014, Dermatology online journal.

[199]  E. Gómez de la Fuente,et al.  Photo-induced erythema multiforme associated with vandetanib administration. , 2014, Journal of the American Academy of Dermatology.

[200]  Philip R. Cohen,et al.  Case of vemurafenib‐induced Sweet's syndrome , 2014, The Journal of dermatology.

[201]  A. Chang,et al.  Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage. , 2014, JAMA dermatology.

[202]  J. Byrd,et al.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. , 2014, The New England journal of medicine.

[203]  G. Sethuraman,et al.  Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings , 2014, Current medical research and opinion.

[204]  K. Tsai,et al.  Histological Features Associated With Vemurafenib-Induced Skin Toxicities: Examination of 141 Cutaneous Lesions Biopsied During Therapy , 2014, The American Journal of dermatopathology.

[205]  P. Fernández-Peñas,et al.  Panniculitis in Patients Treated With BRAF Inhibitors: A Case Series , 2014, The American Journal of dermatopathology.

[206]  H. Kantarjian,et al.  Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management , 2014, American journal of hematology.

[207]  Dirk Schadendorf,et al.  Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. , 2014, The Lancet. Oncology.

[208]  K. Tsai,et al.  Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma , 2014, Journal of cutaneous pathology.

[209]  K. Tsai,et al.  Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions , 2014, International journal of dermatology.

[210]  Yi-long Wu,et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[211]  N. Ormaechea-Pérez,et al.  Adverse skin effects of imatinib, a tyrosine kinase inhibitor. , 2014, Actas dermo-sifiliograficas.

[212]  D. Schadendorf,et al.  Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[213]  Ying Cheng,et al.  Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. , 2013, The Lancet. Oncology.

[214]  C. Ko,et al.  Vemurafenib (PLX-4032)-induced keratoses: verrucous but not verrucae. , 2013, Journal of the American Academy of Dermatology.

[215]  E. Siemers,et al.  A phase 3 trial of semagacestat for treatment of Alzheimer's disease. , 2013, The New England journal of medicine.

[216]  J. Carrascosa,et al.  Pityriasis rubra pilaris‐like reaction induced by imatinib , 2013, Clinical and experimental dermatology.

[217]  M. Thomas,et al.  Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[218]  F. Atalay,et al.  Imatinib-Induced Psoriasis , 2013, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[219]  M. Lacouture,et al.  Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis , 2013, Investigational New Drugs.

[220]  P. Aronson,et al.  Sorafenib induced eruptive melanocytic lesions. , 2013, Dermatology online journal.

[221]  S. Seité,et al.  Vemurafenib: an unusual UVA‐induced photosensitivity , 2013, Experimental dermatology.

[222]  Rajan P. Kulkarni,et al.  Genetic profiling of BRAF inhibitor-induced keratoacanthomas reveals no induction of MAP kinase pathway expression. , 2013, The Journal of investigative dermatology.

[223]  A. Wysong,et al.  New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. , 2013, JAMA dermatology.

[224]  J. Sosman,et al.  Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[225]  A. Kimball,et al.  Cutaneous effects of BRAF inhibitor therapy: a case series. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[226]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[227]  J. Blay,et al.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[228]  M. Lacouture,et al.  The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis , 2013, Investigational New Drugs.

[229]  Praveen Jha,et al.  Imatinib-induced Stevens-Johnsons syndrome , 2013, BMJ Case Reports.

[230]  J. Kim,et al.  The impact of dermatological toxicities of anti‐cancer therapy on the dermatological quality of life of cancer patients , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[231]  G. Long,et al.  Cutaneous toxicities of RAF inhibitors. , 2013, The Lancet. Oncology.

[232]  A. McCullough.  RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors , 2013 .

[233]  E. Ibrahim,et al.  Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis , 2013, International Journal of Clinical Oncology.

[234]  E. Baudin,et al.  A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. , 2012, Archives of dermatology.

[235]  Christopher J. Miller,et al.  Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. , 2012, Journal of the American Academy of Dermatology.

[236]  R. Scolyer,et al.  Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma , 2012, The British journal of dermatology.

[237]  K. Blennow,et al.  Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. , 2012, Archives of neurology.

[238]  Thomas Krause,et al.  Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. , 2012, The Lancet. Oncology.

[239]  K. Flaherty,et al.  Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[240]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[241]  Robert Beckman,et al.  Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[242]  T. Ciuleanu,et al.  Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. , 2012, The Lancet. Oncology.

[243]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[244]  M. Lacouture,et al.  Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. , 2012, The Journal of clinical endocrinology and metabolism.

[245]  Francisco Cervantes,et al.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.

[246]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[247]  I. Sohn,et al.  Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. , 2010, Lung cancer.

[248]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[249]  Jimi Yoon,et al.  Stevens-Johnson Syndrome Induced by Vandetanib , 2011, Annals of dermatology.

[250]  Jeung-Hoon Lee,et al.  Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™) , 2011, Annals of dermatology.

[251]  A. Eggermont,et al.  Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1 , 2011, Clinical Cancer Research.

[252]  H. Akaza,et al.  Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. , 2011, European journal of cancer.

[253]  J. Olson,et al.  Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[254]  R. Maki,et al.  Pigmentary changes in a patient treated with imatinib. , 2011, Journal of drugs in dermatology : JDD.

[255]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[256]  G. Spera,et al.  Reversible hair depigmentation in a patient treated with imatinib. , 2011, Leukemia research.

[257]  J. Wolchok,et al.  Keratoacanthomas associated with imatinib mesylate , 2011, Acta oncologica.

[258]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[259]  S. Bhambri.  Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib , 2011 .

[260]  M. Lacouture,et al.  Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) , 2011, Investigational New Drugs.

[261]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[262]  J. English,et al.  Imatinib mesylate-induced pseudoporphyria. , 2010, Journal of the American Academy of Dermatology.

[263]  A. Gemma,et al.  F1000 highlights , 2010 .

[264]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[265]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[266]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[267]  O. Ishikawa,et al.  Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature. , 2010, Acta dermato-venereologica.

[268]  J. Thachil.  T‐regulatory cell response in psoriasis and changes with imatinib therapy , 2009, Clinical and experimental dermatology.

[269]  H. Skelton,et al.  Eruptive Keratoacanthoma‐Type Squamous Cell Carcinomas in Patients Taking Sorafenib for the Treatment of Solid Tumors , 2009, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[270]  Chih-hsun Yang,et al.  Severe photosensitivity reaction to vandetanib. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[271]  J. Soria,et al.  Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[272]  H. Kong,et al.  Array of cutaneous adverse effects associated with sorafenib. , 2009, Journal of the American Academy of Dermatology.

[273]  M. Bousema,et al.  Imatinib‐induced pseudoporphyria , 2009, Clinical and experimental dermatology.

[274]  Apurva A Desai,et al.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[275]  A. L. Chan,et al.  Stevens-Johnson Syndrome Induced by Combination of Imatinib and Allopurinol , 2009, Chemotherapy.

[276]  H. Kong,et al.  Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy , 2009, Clinical Cancer Research.

[277]  R. Virk,et al.  Management of imatinib‐related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour , 2009, The Australasian journal of dermatology.

[278]  C. Robert,et al.  Dermatologic symptoms associated with the multikinase inhibitor sorafenib. , 2009, Journal of American Academy of Dermatology.

[279]  E. Jonasch,et al.  Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. , 2009, Clinical genitourinary cancer.

[280]  M. Lacouture,et al.  Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[281]  C. Robert,et al.  Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. , 2008, Archives of dermatology.

[282]  D. West,et al.  Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib , 2008, Supportive Care in Cancer.

[283]  S. Youn,et al.  Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib , 2007, The Journal of dermatology.

[284]  E. Raymond,et al.  Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST) , 2007, Therapeutics and clinical risk management.

[285]  A. Tan,et al.  Sweet's syndrome: a spectrum of unusual clinical presentations and associations , 2007, The British journal of dermatology.

[286]  J. Borrás-Blasco,et al.  Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases , 2006, International journal of dermatology.

[287]  N. Shibagaki,et al.  Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia , 2006, The British journal of dermatology.

[288]  T. Čufer,et al.  Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer , 2006, Anti-cancer drugs.

[289]  F. Passamonti,et al.  Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases. , 2005, Journal of the American Academy of Dermatology.

[290]  Peter Carmeliet,et al.  VEGF as a Key Mediator of Angiogenesis in Cancer , 2005, Oncology.

[291]  K. Pavithran,et al.  Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose. , 2005, Indian journal of dermatology, venereology and leprology.

[292]  G. Mills,et al.  Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia. , 2005, Archives of dermatology.

[293]  G. Scott,et al.  Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy. , 2005, Leukemia research.

[294]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[295]  T. Ahmed,et al.  Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate. , 2004, Leukemia research.

[296]  A. Boisseau-Garsaud,et al.  [Lichenoid cutaneous reaction to imatinib]. , 2004, Annales de dermatologie et de venereologie.

[297]  F. Mandelli,et al.  Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia , 2004, Leukemia.

[298]  K. Schäkel,et al.  Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation , 2003, Annals of Hematology.

[299]  G. Mufti,et al.  Precipitation of porphyria cutanea tarda by imatinib mesylate? , 2003, British journal of haematology.

[300]  B. Dörken,et al.  Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment , 2003, European journal of haematology.

[301]  M. Duvic,et al.  Mycosis fungoides‐like reaction in a patient treated with Gleevec , 2003, Journal of cutaneous pathology.

[302]  E. Raymond,et al.  Tyrosine kinase inhibition and grey hair , 2003, The Lancet.

[303]  J. Larghero,et al.  Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate , 2003, British journal of haematology.

[304]  M. Tulliez,et al.  Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. , 2003, Journal of the American Academy of Dermatology.

[305]  D. Tsambaos,et al.  Disseminated erythematous and pityriasiform plaques caused by imatinib mesylate. , 2003, Acta dermato-venereologica.

[306]  B. Dörken,et al.  Imatinib‐induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia , 2002, European journal of haematology.

[307]  J. Muir,et al.  Oral Lichenoid Reaction to Imatinib (STI 571, Gleevec) , 2002, Dermatology.

[308]  K. Konstantopoulos,et al.  Pityriasis rosea Associated with Imatinib (STI571, Gleevec) , 2002, Dermatology.

[309]  S. Hirota,et al.  Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour , 2002, The British journal of dermatology.

[310]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[311]  R. Gale,et al.  Chronic myeloid leukemia. , 1992, The American journal of medicine.

[312]  B. Adam.  Cutaneous drug eruptions. , 1982, The Medical journal of Malaysia.